How Can CDMOs Reduce Product Loss During Aseptic Filling?
Reducing product loss is one of the highest priorities for CDMOs and biotech manufacturers handling expensive injectable drugs. This is especially important for peptide therapeutics, biologics, and GLP-1 products where even small filling losses can significantly increase production costs.
Modern aseptic filling systems reduce product waste through several technologies.
Vacuum-assisted filling improves dosing stability and minimizes dripping during filling operations. Rotary piston systems provide highly accurate dosing for high-viscosity products. Peristaltic pump systems also help maintain sterility while reducing contamination risks.
Many CDMOs are also adopting RTU nested syringe and cartridge systems because they simplify aseptic processing and reduce manual handling.
To minimize product loss, biotech manufacturers often prioritize:
- Precision filling systems
- Stable dosing technology
- Fast changeover capability
- Automated stoppering
- Nitrogen purging
- Reduced dead volume
Flexible modular systems are especially attractive because they support small-batch production with lower waste levels. Compact aseptic platforms also improve operational efficiency in limited cleanroom spaces.
As high-value injectable therapies continue growing across North America, reducing product loss has become a critical competitive advantage for CDMOs and biotech companies.
Contact our engineer for your solution!